Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
SAN DIEGO, Nov. 14, 2017 -- Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, will participate today in a presentation on the development of its two anti-BCMA CAR-T programs: P-BCMA-101, the company’s BCMA-specific CAR-T drug candidate in a Phase 1 clinical trial for the treatment of multiple myeloma, and P-BCMA-ALLO1, the company’s universal CAR-T program also targeting BCMA in hematologic cancers.
The presentation expands on the anti-BCMA CAR-T development programs featuring Poseida’s proprietary piggyBac™ non-viral gene delivery system and Centyrin™ binding domain. P-BCMA-101 exhibits no signs of CAR-mediated ‘tonic signaling’, which has been described to occur for some traditional single chain variable fragment (scFv)-based CARs and can lead to diminished function and poor durability. Greater persistence of P-BCMA-101 may also be facilitated by an exceptionally high percentage (>70%) of the highly desirable stem cell memory T cell subtype (Tscm), a cell type recently discovered to be extremely long-lived and capable of giving rise to large amounts of potent tumor killing T cells upon tumor cell detection.
The discussion also features the development of an allogeneic anti-BCMA CAR-T therapy, called P-BCMA-ALLO1, produced with Poseida’s piggyBac™ DNA Modification System and proprietary NextGEN™ CRISPR site-specific nucleases. These cells express the same transgenic elements of P-BCMA-101 including a safety switch, a BCMA-specific CAR and a positive selection gene, but lack expression of endogenous T cell receptor and beta-2 microglobulin, two major proteins associated with alloreactivity. In addition, data show that gene editing of P-BCMA-ALLO1 cells does not reduce their ability to kill tumor cells in vitro.
The presentation titled “P-BCMA-101: A BCMA-Specific CAR-T Stem Cell Memory Therapy for Multiple Myeloma” by Devon J. Shedlock, Ph.D., vice president of preclinical development at Poseida, takes place today at 2:30 p.m. PT at the Precision: Blood Cancer Summit 2017 in San Francisco.
About P-BCMA-101
P-BCMA-101 is a CAR-T immunotherapy designed to supercharge a patient’s own T cells to safely and effectively eliminate tumor cells carrying B cell maturation antigen (BCMA), which is expressed on essentially all multiple myeloma cells. P-BCMA-101 modifies a patient’s T cells using piggyBac™, which enables several desirable features, including:
- T stem cell memory: P-BCMA-101 is comprised of an exceptionally high proportion of stem cell memory T cells, resulting in unprecedented durability of response without re-administration of product in multiple preclinical studies.
- Pure product: The addition of a human-derived positive selection gene results in a product that is essentially 100% pure in contrast with lentivirus-based products, which are generally 5-30% pure.
- Safety: piggyBac™ has safer integration profile than lentivirus and is non-oncogenic. In addition, a human-derived safety switch is added such that P-BCMA-101 can be rapidly attenuated or eliminated if significant side effects occur.
Additional information about the Phase 1 clinical study of P-BCMA-101 is available at www.clinicaltrials.gov using identifier: NCT03288493
About Poseida Therapeutics, Inc.
Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac™ DNA Modification System, XTN™ TALEN and NextGEN™ CRISPR site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE). For more information, visit www.poseida.com.
Corporate Communications Contact:
Jason Spark
Canale Communications
619-849-6005
[email protected]
